Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (10,874)	$ (8,475)	$ (11,275)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of real estate, net	0	(1,846)	0
Gain on sale of subsidiaries, net of adjustments	0	(739)	(3,430)
Depreciation and amortization	2,211	1,220	2,200
Amortization of debt discount	780	0	0
Amortization of deferred financing fees	385	343	298
Provision for bad debt expense	61	85	(380)
Share-based compensation expense	440	503	643
Impairment of long-lived assets, loss on disposal of fixed assets and other	0	181	416
Change in assets and liabilities:
Accounts receivable	(1,530)	5,135	9,000
Inventories	215	(300)	(62)
Other assets	(459)	1,005	(184)
Accounts payable, accrued expenses and other liabilities	2,474	(542)	(4,255)
Net cash used in operating activities	(6,297)	(3,430)	(7,029)
Cash flows from investing activities:
Capital expenditures	(793)	(1,409)	(1,550)
Acquisition of Accountable Health Solutions	(4,000)	0	0
Proceeds from sale of real estate, net of closing costs	0	2,544	0
Proceeds from the sale of Heritage Labs and Hooper Holmes Services	0	3,539	0
Cost paid to sell Heritage Labs and Hooper Holmes Services	0	(777)	0
Proceeds from the sale of Portamedic	0	743	6,053
Costs paid to sell Portamedic	0	0	(781)
Net cash (used in) provided by investing activities	(4,793)	4,640	3,722
Cash flows from financing activities:
Borrowings under credit facility	19,190	0	50,827
Payments under credit facility	(15,912)	0	(50,827)
Proceeds from issuance of Term Loan	5,000	0	0
Debt financing fees	(377)	0	(999)
Proceeds related to the exercise of stock options	23	29	71
Payments on capital lease obligations	0	(8)	(114)
Net cash provided by (used in) financing activities	7,924	21	(1,042)
Net increase (decrease) in cash and cash equivalents	(3,166)	1,231	(4,349)
Cash and cash equivalents at beginning of year	5,201	3,970	8,319
Cash and cash equivalents at end of year	2,035	5,201	3,970
Supplemental disclosure of non-cash investing activities:
Fixed assets vouchered but not paid	97	163	153
Debt financing fees vouchered but not paid	500	0	0
Proceeds from sale of Portamedic not received, net of costs not paid	0	0	1,525
Supplemental disclosure of non-cash financing activities:
Issuance of common stock in connection with the Acquisition	3,000	0	0
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	516	0	82
Cash paid during the period for income taxes	$ 41	$ 53	$ 62